Screener / SEC EDGAR /CIK 0001668397 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Research Services

Medpace Holdings, Inc. MEDP

Compare with peers Embed
FY2025 at a glance

Sales up 20.0%, free cash flow up to $681.9M

XBRL, from each 10-K
RevenueStatements
$2.5B from $2.1B in FY2024
FY2016FY2025
Net incomeStatements
$451.1M from $404.4M in FY2024
FY2016FY2025
Free cash flowStatements
$681.9M from $572.3M in FY2024
FY2016FY2025
EPS (diluted)Statements
$15.28 from $12.63 in FY2024
FY2016FY2025
Operating marginStatements
21.1% from 21.2% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
18.01
Sales (ttm)
2.8B
Net income (ttm)
517.8M
Sales growth
+20.0%
EPS growth
+21.0%
Sales Q/Q
+8.5%
Free cash flow
667.6M
Gross margin
-
Oper. margin
21.4%
Net margin
18.2%
FCF margin
23.5%
R&D / sales
-
Dividend
-
Debt/Eq
-
Curr. ratio
0.83
Cash
705.3M
Op. cash flow (ttm)
723.0M
EBITDA
562.1M
EBITDA margin
22.2%
Quick ratio
0.83
ROIC
76.1%
FCF after stock pay
647.1M
Goodwill / assets
33.5%
Oper. margin low 5y
17.4%
Tax rate
16.8%
Stock pay / sales
1.4%
Shares out.
28.0M
Shares Y/Y
-7.8%
Book / share
20.91
Cash / share
25.22
Sales / share
101.47
Asset turnover
1.23
Days sales out.
58
Sales 3Y CAGR
+20.1%
Sales 5Y CAGR
+22.3%
EPS 3Y CAGR
+28.0%
EPS 5Y CAGR
+31.8%
Employees
6,200
Sales / employee
458K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 2.5B +22.0% a year Net income 451.1M +47.8% a year
FY2016 revenue 421.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-004451 FY2016 net income 13.4M · NetIncomeLoss, 0001564590-19-004451 421.6M FY2016 FY2017 revenue 436.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-006385 FY2017 net income 39.1M · NetIncomeLoss, 0001564590-20-006385 436.2M FY2017 FY2018 revenue 704.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-006072 FY2018 net income 73.2M · NetIncomeLoss, 0001564590-21-006072 704.6M FY2018 FY2019 revenue 861.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-22-001280 FY2019 net income 100.4M · NetIncomeLoss, 0000950170-22-001280 861.0M FY2019 FY2020 revenue 925.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-23-000008 FY2020 net income 145.4M · NetIncomeLoss, 0001668397-23-000008 925.9M FY2020 FY2021 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-24-000013 FY2021 net income 181.8M · NetIncomeLoss, 0001668397-24-000013 1.1B FY2021 FY2022 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-25-000017 FY2022 net income 245.4M · NetIncomeLoss, 0001668397-25-000017 1.5B FY2022 FY2023 revenue 1.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-26-000006 FY2023 net income 282.8M · NetIncomeLoss, 0001668397-26-000006 1.9B FY2023 FY2024 revenue 2.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-26-000006 FY2024 net income 404.4M · NetIncomeLoss, 0001668397-26-000006 2.1B FY2024 FY2025 revenue 2.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001668397-26-000006 FY2025 net income 451.1M · NetIncomeLoss, 0001668397-26-000006 2.5B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
0 1000 2000 3000 100 Revenue: $421.6M in FY2016, $2.5B in FY2025 REVENUE $2.5B · 6.0x Net income: $13.4M in FY2016, $451.1M in FY2025 NET INCOME $451.1M · 33.6x Free cash flow: $78.2M in FY2016, $681.9M in FY2025 FREE CASH FLOW $681.9M · 8.7x FY2016 = 100FY2021FY2025
Revenue 6.0x $421.6M to $2.5B
Net income 33.6x $13.4M to $451.1M
Free cash flow 8.7x $78.2M to $681.9M

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +51.2% a year FY2016 $0.37 to FY2025 $15.28, 9 years
Book value per share +1.7% a year FY2015 $13.19 to FY2025 $15.55, 10 years
Free cash flow per share +24.7% a year FY2015 $2.53 to FY2025 $23.09, 10 years
500 100 Book value / share: $13.19 in FY2015, $15.55 in FY2025 BOOK VALUE / SHARE $15.55 · 1.2x FCF / share: $2.53 in FY2015, $23.09 in FY2025 FCF / SHARE $23.09 · 9.1x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $15.28$15.55$23.09
Dec 31, 2024 $12.63$25.79$17.88
Dec 31, 2023 $8.88$17.55$12.46
Dec 31, 2022 $7.28$11.48$10.43
Dec 31, 2021 $4.81$25.28$6.24
Dec 31, 2020 $3.84$21.37$6.03
Dec 31, 2019 $2.67$19.33$4.90
Dec 31, 2018 $1.97$16.22$3.81
Dec 31, 2017 $0.98$12.78$2.15
Dec 31, 2016 $0.37$16.81$2.15
Dec 31, 2015 -$0.28$13.19$2.53

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $989.6M
  • − All liabilities $1.5B
  • = Net current asset value -$526.8M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $459.1M
  • − Goodwill $662.4M
  • − Other intangible assets $33.4M
  • = Tangible book value -$236.7M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

MEDP against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+20.0%40th of 155 · median +10.5%
Net margin
-4.1%15.3%
18.2%31st of 154 · median 6.8%
Return on equity
-5.2%18.5%
88.5%1st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
23.5%22nd of 145 · median 10.0%
MEDP and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
MEDP Medpace Holdings, Inc.$2.8B +20.0%-18.2%88.5%23.5%-
BKD Brookdale Senior Living Inc.$2.9B +2.2%27.6%-1.3%-0.5%-
RVTY Revvity$2.9B +3.7%-8.6%3.5%20.1%0.36
NTRA Natera, Inc.$2.9B +35.9%--5.7%-8.8%1.8%0.04
NVST Envista Holdings Corp$2.9B +8.3%55.9%22.0%20.5%8.4%0.46
HIMS Hims & Hers Health, Inc.$2.9B +59.0%63.8%-6.7%-53.7%0.3%-
All 162 companies in the group

Where the $2.5B of revenue came from

by product, year to Dec 31, 2025

  • Oncology $747.6M · 30%
  • Other $745.0M · 29%
  • Metabolic $408.5M · 16%
  • AVAI $254.8M · 10%
  • Central Nervous System $239.4M · 9%
  • Cardiology $134.9M · 5%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 98.3% FY2020: 18.0% net income ÷ equity
Net margin 17.8% FY2020: 15.7% profit per $ of sales: 451.1M ÷ 2.5B
Asset turnover 1.28× FY2020: 0.67× sales per $ of assets: 2.5B ÷ 2.0B
Leverage 4.30× FY2020: 1.73× assets per $ of equity: 2.0B ÷ 459.1M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    18.2% vs 6.8%
  • Return on equity above 15%
    88.5%
  • A profit in every one of 10 years
Net margin, FY2016 to FY2025: 3.2% to 17.8%

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $681.9M last year
  • Share count down over 5 years
    −21.7%
  • Cash from operations above net income
    $713.2M vs $451.1M
Free cash flow, FY2016 to FY2025: 78.2M to 681.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Remaining performance obligations

Signed, not yet recognized $3.8B revenue under contracts the company has not delivered yet, Sep 30, 2026 · +8.6% on a year earlier

Contract liabilities, current part

Paid in advance $961.9M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +15.3% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

MEDP's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue2.5B
FY2016: 421.6MFY2017: 436.2MFY2018: 704.6MFY2019: 861.0MFY2020: 925.9MFY2021: 1.1BFY2022: 1.5BFY2023: 1.9BFY2024: 2.1BFY2025: 2.5B FY2017FY2019FY2021FY2023FY2025
Net income451.1M
FY2016: 13.4MFY2017: 39.1MFY2018: 73.2MFY2019: 100.4MFY2020: 145.4MFY2021: 181.8MFY2022: 245.4MFY2023: 282.8MFY2024: 404.4MFY2025: 451.1M FY2017FY2019FY2021FY2023FY2025
Free cash flow681.9M
FY2016: 78.2MFY2017: 85.7MFY2018: 140.6MFY2019: 184.0MFY2020: 227.3MFY2021: 235.1MFY2022: 351.2MFY2023: 396.7MFY2024: 572.3MFY2025: 681.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay647.1M
FY2016: 68.4MFY2017: 81.2MFY2018: 134.1MFY2019: 163.2MFY2020: 213.6MFY2021: 220.6MFY2022: 329.8MFY2023: 376.2MFY2024: 546.8MFY2025: 647.1M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)15.28
FY2016: 0.37FY2017: 0.98FY2018: 1.97FY2019: 2.67FY2020: 3.84FY2021: 4.81FY2022: 7.28FY2023: 8.88FY2024: 12.63FY2025: 15.28 FY2017FY2019FY2021FY2023FY2025
Diluted shares29.5M
FY2016: 36.3MFY2017: 39.8MFY2018: 36.9MFY2019: 37.6MFY2020: 37.7MFY2021: 37.7MFY2022: 33.7MFY2023: 31.8MFY2024: 32.0MFY2025: 29.5M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Oncology 747.6M29.5% +14.8%
Other 745.0M29.4% +62.8%
Metabolic 408.5M16.1% -5.3%
AVAI 254.8M10.1% +40.0%
Central Nervous System 239.4M9.5% +3.9%
Cardiology 134.9M5.3% -13.8%

10-K 0001668397-26-000006, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue421.6M436.2M704.6M861.0M925.9M1.1B1.5B1.9B2.1B2.5B
SG&A61.5M63.4M75.7M95.2M92.2M108.4M131.4M161.4M180.2M197.6M
Operating income52.5M64.9M101.0M127.3M167.0M198.6M278.7M336.8M446.9M534.9M
Interest expense16.9M6.9M7.6M1.5M104K123K2.9M3.1M171K0
Pretax income22.0M56.9M94.0M124.8M168.5M201.9M282.9M335.7M475.9M542.4M
Income tax8.5M17.8M20.8M24.4M23.1M20.0M37.5M52.9M71.5M91.3M
Net income13.4M39.1M73.2M100.4M145.4M181.8M245.4M282.8M404.4M451.1M
EPS (diluted)0.370.981.972.673.844.817.288.8812.6315.28
Diluted shares36.3M39.8M36.9M37.6M37.7M37.7M33.7M31.8M32.0M29.5M
Depreciation & amortization7.4M8.6M9.2M8.4M11.7M16.0M19.0M24.1M27.8M27.2M
EBITDA59.9M73.4M110.3M135.6M178.7M214.6M297.7M361.0M474.7M562.1M
Operating margin12.5%14.9%14.3%14.8%18.0%17.4%19.1%17.9%21.2%21.1%
Net margin3.2%9.0%10.4%11.7%15.7%15.9%16.8%15.0%19.2%17.8%
Revenue growth+17.4%+3.5%+61.5%+22.2%+7.5%+23.4%+27.8%+29.2%+11.8%+20.0%
EPS growth-+165%+101%+35.5%+43.8%+25.3%+51.4%+22.0%+42.2%+21.0%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow91.7M97.4M156.6M201.9M258.7M263.3M388.1M433.4M608.8M713.2M
Capital spending13.5M11.7M16.0M17.9M31.3M28.3M36.9M36.6M36.5M31.4M
Free cash flow78.2M85.7M140.6M184.0M227.3M235.1M351.2M396.7M572.3M681.9M
Stock-based pay (added back)9.8M4.5M6.5M20.7M13.8M14.5M21.4M20.5M25.5M34.8M
Free cash flow after stock pay68.4M81.2M134.1M163.2M213.6M220.6M329.8M376.2M546.8M647.1M
Buybacks0155.6M0098.3M62.1M847.8M144.0M169.9M917.4M
Debt raised164.5M00-------
Debt repaid390.1M12.4M72.2M80.4M00----
Investing cash flow-13.4M-12.2M-17.0M-19.1M-31.2M-31.4M-38.7M-34.6M-28.3M-31.1M
Financing cash flow-58.0M-97.8M-141.6M-73.9M-82.3M-44.5M-775.8M-182.6M-154.0M-860.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)9.8M4.5M6.5M20.7M13.8M14.5M21.4M20.5M25.5M34.8M
Stock-based pay / revenue2.3%1.0%0.9%2.4%1.5%1.3%1.5%1.1%1.2%1.4%
Operating lease cost---13.2M19.8M23.9M25.9M27.9M31.6M31.1M
Operating lease cash paid---9.8M14.0M16.3M17.0M19.8M22.4M25.9M
Right-of-use assets--052.2M113.8M129.6M139.1M144.8M128.6M117.8M
Operating lease liabilities---56.2M131.0M147.2M158.1M164.5M149.5M136.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MEDP/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.